← Back
Data updated: Jul 17, 2026
US ARMY MED RES
Pharma Pharmaceuticals
US ARMY MED RES is a pharmaceutical company with 1 FDA-approved products.
2000
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Upcoming FDA Decisions
Full Calendar → Aug 13, 2026 — LNTH
26d Oct 17, 2026 — Phentolamine ophthalmic solution 0.75%
US ARMY MED RES's Key Drugs
US ARMY MED RES's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
US ARMY MED RES's Recent FDA Approvals
New NDA/BLA approvals for US ARMY MED RES over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
US ARMY MED RES's Therapeutic Areas
Disease areas where US ARMY MED RES has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
US ARMY MED RES Pipeline Snapshot
Active clinical trials for US ARMY MED RES across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2000-02-17
- Latest
- 2002-05-06
- Applications
- 1